AVDL Fundamental Analysis - AVADEL PHARMACEUTICALS

Fundamental Rating

Taking everything into account, AVDL scores 5 out of 10 in our fundamental rating. AVDL was compared to 197 industry peers in the Pharmaceuticals industry. AVDL is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. AVDL is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!

Quickly go to:

1. Profitability

1.1 Basic Checks

AVDL had negative earnings in the past year.

In the past year AVDL had a positive cash flow from operations.

In the past 5 years AVDL reported 4 times negative net income.

AVDL had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

AVDL has a better Return On Assets (-1.56%) than 76.53% of its industry peers.

AVDL's Return On Equity of -3.22% is fine compared to the rest of the industry. AVDL outperforms 78.06% of its industry peers.

AVDL has a Return On Invested Capital of 1.37%. This is in the better half of the industry: AVDL outperforms 78.57% of its industry peers.

		Industry Rank	Sector Rank
ROA	-1.56%
ROE	-3.22%
ROIC	1.37%

ROA(3y)-76.86%

ROA(5y)-51.92%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a decent Operating Margin value of 1.02%, AVDL is doing good in the industry, outperforming 78.06% of the companies in the same industry.

AVDL has a better Gross Margin (89.64%) than 93.37% of its industry peers.

In the last couple of years the Gross Margin of AVDL has grown nicely.

		Industry Rank	Sector Rank
OM	1.02%
PM (TTM)	N/A
GM	89.64%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y2.73%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), AVDL is destroying value.

The number of shares outstanding for AVDL has been increased compared to 1 year ago.

The number of shares outstanding for AVDL has been increased compared to 5 years ago.

AVDL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 5.11 indicates that AVDL is not in any danger for bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 5.11, AVDL is in the better half of the industry, outperforming 78.57% of the companies in the same industry.

There is no outstanding debt for AVDL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Altman-Z	5.11

ROIC/WACC0.18

WACC7.49%

2.3 Liquidity

A Current Ratio of 2.79 indicates that AVDL has no problem at all paying its short term obligations.

AVDL's Current ratio of 2.79 is in line compared to the rest of the industry. AVDL outperforms 53.06% of its industry peers.

AVDL has a Quick Ratio of 2.38. This indicates that AVDL is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of AVDL (2.38) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	2.79
Quick Ratio	2.38

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 97.37% over the past year.

The Revenue has grown by 132.35% in the past year. This is a very strong growth!

The Revenue has been growing by 23.35% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)97.37%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%171.43%

Revenue 1Y (TTM)132.35%

Revenue growth 3YN/A

Revenue growth 5Y23.35%

Sales Q2Q%64.15%

3.2 Future

AVDL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 46.24% yearly.

Based on estimates for the next years, AVDL will show a very strong growth in Revenue. The Revenue will grow by 23.79% on average per year.

EPS Next Y146.52%

EPS Next 2Y88.55%

EPS Next 3Y61.75%

EPS Next 5Y46.24%

Revenue Next Year61.7%

Revenue Next 2Y45.32%

Revenue Next 3Y37.19%

Revenue Next 5Y23.79%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AVDL. In the last year negative earnings were reported.

The Price/Forward Earnings ratio is 20.03, which indicates a rather expensive current valuation of AVDL.

77.04% of the companies in the same industry are more expensive than AVDL, based on the Price/Forward Earnings ratio.

AVDL's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.86.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	20.03

4.2 Price Multiples

AVDL's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. AVDL is cheaper than 75.51% of the companies in the same industry.

Based on the Price/Free Cash Flow ratio, AVDL is valued a bit cheaper than 76.02% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	278.59
EV/EBITDA	234.05

4.3 Compensation for Growth

AVDL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

AVDL's earnings are expected to grow with 61.75% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y88.55%

EPS Next 3Y61.75%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

AVDL does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AVADEL PHARMACEUTICALS

NASDAQ:AVDL (9/19/2025, 8:00:01 PM)

After market: 16.2 0 (0%)

16.2

-0.03 (-0.18%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-07 2025-08-07/bmo

Earnings (Next)11-10 2025-11-10/bmo

Inst Owners83.09%

Inst Owner Change4.07%

Ins Owners4.83%

Ins Owner Change1.1%

Market Cap1.47B

Analysts84.29

Price Target20.6 (27.16%)

Short Float %12.17%

Short Ratio8.27

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)144.64%

Min EPS beat(2)31.2%

Max EPS beat(2)258.07%

EPS beat(4)3

Avg EPS beat(4)78.96%

Min EPS beat(4)-20.15%

Max EPS beat(4)258.07%

EPS beat(8)4

Avg EPS beat(8)33.56%

EPS beat(12)4

Avg EPS beat(12)3.14%

EPS beat(16)6

Avg EPS beat(16)-5.8%

Revenue beat(2)2

Avg Revenue beat(2)5.07%

Min Revenue beat(2)1.52%

Max Revenue beat(2)8.61%

Revenue beat(4)3

Avg Revenue beat(4)2.45%

Min Revenue beat(4)-1.22%

Max Revenue beat(4)8.61%

Revenue beat(8)7

Avg Revenue beat(8)7.62%

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)17.1%

PT rev (3m)12.85%

EPS NQ rev (1m)6.81%

EPS NQ rev (3m)-27.7%

EPS NY rev (1m)5.73%

EPS NY rev (3m)56.35%

Revenue NQ rev (1m)1.15%

Revenue NQ rev (3m)4.4%

Revenue NY rev (1m)4.96%

Revenue NY rev (3m)5.52%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	20.03
P/S	6.64
P/FCF	278.59
P/OCF	269.34
P/B	16.18
P/tB	19.86
EV/EBITDA	234.05

EPS(TTM)-0.03

EYN/A

EPS(NY)0.81

Fwd EY4.99%

FCF(TTM)0.06

FCFY0.36%

OCF(TTM)0.06

OCFY0.37%

SpS2.44

BVpS1

TBVpS0.82

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-1.56%
ROE	-3.22%
ROCE	1.74%
ROIC	1.37%
ROICexc	3.68%
ROICexgc	5.63%
OM	1.02%
PM (TTM)	N/A
GM	89.64%
FCFM	2.38%

ROA(3y)-76.86%

ROA(5y)-51.92%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y2.73%

F-Score5

Asset Turnover1.18

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Debt/EBITDA	0
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	0.24
Cash Conversion	93.05%
Profit Quality	N/A
Current Ratio	2.79
Quick Ratio	2.38
Altman-Z	5.11

F-Score5

WACC7.49%

ROIC/WACC0.18

Cap/Depr(3y)15.99%

Cap/Depr(5y)11.39%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)97.37%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%171.43%

EPS Next Y146.52%

EPS Next 2Y88.55%

EPS Next 3Y61.75%

EPS Next 5Y46.24%

Revenue 1Y (TTM)132.35%

Revenue growth 3YN/A

Revenue growth 5Y23.35%

Sales Q2Q%64.15%

Revenue Next Year61.7%

Revenue Next 2Y45.32%

Revenue Next 3Y37.19%

Revenue Next 5Y23.79%

EBIT growth 1Y102.29%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year186.69%

EBIT Next 3Y90.38%

EBIT Next 5Y44.74%

FCF growth 1Y106.19%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y106.45%

OCF growth 3YN/A

OCF growth 5YN/A

AVADEL PHARMACEUTICALS (AVDL) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens